Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation

Go Makimoto, Tatsuya Nishi, Keita Kawakado, Tomoka Nishimura, Tomoki Tamura, Kenichiro Kudo, Shoichi Kuyama

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.

Original languageEnglish
Pages (from-to)2161-2164
Number of pages4
JournalInternal Medicine
Volume59
Issue number17
DOIs
Publication statusPublished - Sep 1 2020
Externally publishedYes

Keywords

  • Desensitization
  • Epidermal growth factor receptor
  • Non-small-cell lung cancer
  • Osimertinib

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Successful desensitization treatment with osimertinib after the development of osimertinib-induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation'. Together they form a unique fingerprint.

Cite this